NYSEAM:AGE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$55.0m

Last Updated

2021/06/17 03:14 UTC

Data Sources

Company Financials

Executive Summary

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has AgeX Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AGE's weekly volatility has decreased from 31% to 10% over the past year.


Market Performance


7 Day Return

-13.8%

AGE

-2.5%

US Biotechs

-0.2%

US Market


1 Year Return

58.5%

AGE

23.1%

US Biotechs

39.4%

US Market

Return vs Industry: AGE exceeded the US Biotechs industry which returned 23.1% over the past year.

Return vs Market: AGE exceeded the US Market which returned 39.7% over the past year.


Shareholder returns

AGEIndustryMarket
7 Day-13.8%-2.5%-0.2%
30 Day16.0%5.1%3.1%
90 Day-26.6%3.3%5.6%
1 Year58.5%58.5%24.9%23.1%41.7%39.4%
3 Yearn/a6.2%1.8%59.7%49.9%
5 Yearn/a54.6%42.5%122.6%97.6%

Long-Term Price Volatility Vs. Market

How volatile is AgeX Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AgeX Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether AgeX Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AgeX Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is AgeX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AgeX Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has AgeX Therapeutics performed over the past 5 years?

-7.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGE is currently unprofitable.

Growing Profit Margin: AGE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGE is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.

Accelerating Growth: Unable to compare AGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: AGE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is AgeX Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AGE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AGE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AGE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 3.9% each year


Dividend

What is AgeX Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Mike West (67 yo)

4.42yrs

Tenure

US$561,032

Compensation

Dr. Michael D. West, also known as Mike, Ph.D., has been Chief Executive Officer of AgeX Therapeutics, Inc. since January 2017 and serves as its President. He is a Founder of AgeX Therapeutics, Inc. He has...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD561.03K) is about average for companies of similar size in the US market ($USD526.90K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AGE's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: AGE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AgeX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AgeX Therapeutics, Inc.
  • Ticker: AGE
  • Exchange: NYSEAM
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$55.006m
  • Shares outstanding: 37.94m
  • Website: https://www.agexinc.com

Number of Employees


Location

  • AgeX Therapeutics, Inc.
  • 1101 Marina Village Parkway
  • Suite 201
  • Alameda
  • California
  • 94501
  • United States

Listings


Biography

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 03:14
End of Day Share Price2021/06/16 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.